DDInter1848 DDInter1491
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trast
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Trastuzumab emtansine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Trastuzumab emtansine {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Trastuzumab emtansine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Trastuzumab emtansine {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Trastuzumab emtansine {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Warfarin {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Pomalidomide
Trastuzumab emtansine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} (Compound) binds {v} (Gene) TNF
TNF {u} (Gene) is bound by {v} (Compound) Pomalidomide
Trastuzumab emtansine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Trastuzumab emtansine {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Cabozantinib {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Trastuzumab emtansine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Idelalisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Trastuzumab emtansine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Erwinia chrysanthemi
Asparaginase Erwinia chrysanthemi {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) resembles Pomalidomide (Compound)
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Warfarin and Warfarin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pomalidomide (Compound)
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) binds TNF (Gene) and TNF (Gene) is bound by Pomalidomide (Compound)
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) resembles Pomalidomide (Compound)
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparaginase Erwinia chrysanthemi may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) resembles Pomalidomide (Compound)